Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12023MR)

This product GTTS-WQ12023MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12023MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7170MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ13282MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ5123MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ6507MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ15559MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ12764MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ9671MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ8100MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW